Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148427 | 0.87 | MAPT (0.54) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL5150812 | 0.87 | MAPT (0.54) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL4869419 | 0.83 | MAPT (0.60) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL5150469 | 0.82 | MAPT (0.75) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL5154707 | 0.82 | MAPT (0.68) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL5154642 | 0.82 | MAPT (0.50) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL5261443 | 0.81 | MAPT (0.48) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL4868784 | 0.80 | MEN1 (0.50) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL3802396 | 0.80 | MAPT (0.53) | MAPTMAPK1POLBKDM4EALDH1A1 | |
| SCHEMBL5154998 | 0.79 | MAPT (0.60) | MAPTMAPK1POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451162-A4 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7153880-B2 | Substituted diphenyl heterocycles useful for treating HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-7115642-B2 | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040266840-A1 | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2004-12-30 | — | — | US | disclosed |
| US-20040236112-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2004-11-25 | — | — | US | disclosed |
| WO-2004099164-A1 | SUBSTITUTED DIPHENYL ISOXAZOLES, PYRAZOLES AND OXADIAZOLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1451162-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6759538-B2 | PREVENTION INFECTIONS OF HEPATITIS C VIRUS | RIGEL PHARMACEUTICALS, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2003-09-04 | — | — | US | disclosed |
| WO-2003040112-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266840-A1 | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection | HAVCR2, MAVS, RPL35 | MAPT 4321/4885MAPK1 1732/4885POLB 577/4885 |
| US-20040236112-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | HAVCR2, HCCS, PCNA | MAPT 4524/4885MAPK1 1644/4885POLB 384/4885 |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | HAVCR2, HCCS, PCNA | MAPT 4524/4885MAPK1 1644/4885POLB 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.